Thematische Bibliographien / Antineoplastika

Inhaltsverzeichnis

  1. Zeitschriftenartikel
  2. Dissertationen
  3. Bücher
  4. Buchteile
  5. Konferenzberichte
  6. Berichte der Organisationen

Auswahl der wissenschaftlichen Literatur zum Thema „Antineoplastika“

Autor: Grafiati
Veröffentlicht am 28. Juni 2021
Zuletzt aktualisiert am 1. Februar 2022

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Antineoplastika" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Zeitschriftenartikel zum Thema "Antineoplastika"

1

Kreutzberger, Alfred, und Elfriede Kreutzberger. „Antineoplastika, 15. Mitt. Butylderivate der 5-Aminomethylenbarbitursäure“. Archiv der Pharmazie 318, Nr. 9 (1985): 821–24. http://dx.doi.org/10.1002/ardp.19853180910.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Kreutzberger, Alfred, und Michael Sellheim. „Antineoplastika XVI [1]. 4-Alkyl-6-trifluormethyl-2-ureidopyrimidine“. Journal of Fluorine Chemistry 27, Nr. 2 (Februar 1985): 203–12. http://dx.doi.org/10.1016/s0022-1139(00)84989-1.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Kreutzberger, Alfred, Peter Langner und Jörg Stratmann. „Antineoplastika, 19. Mitt.: Darstellung vonN-[2-Chlor-4-diethylamino-(1,3,5-triazin-6-yl)]-aminosäuren“. Archiv der Pharmazie 323, Nr. 12 (1990): 995–96. http://dx.doi.org/10.1002/ardp.19903231211.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Kreutzberger, Alfred, Peter Langner und Jörg Stratmann. „Antineoplastika, 17. Mitt.1): Darstellung mono- und disubstituierter 2,4-Dichlor-6-diethylamino-1,3,5-triazine“. Archiv der Pharmazie 324, Nr. 3 (1991): 173–76. http://dx.doi.org/10.1002/ardp.19913240308.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Burgaz, S., B. Karahalil, Z. Canli, F. Terzioglu, G. Ançel, R. BM Anzion, R. P. Bos und E. Hüttner. „Assessment of genotoxic damage in nurses occupationally exposed to antineoplastics by the analysis of chromosomal aberrations“. Human & Experimental Toxicology 21, Nr. 3 (März 2002): 129–35. http://dx.doi.org/10.1191/0960327102ht230oa.

Der volle Inhalt der Quelle
Annotation:
To estimate the genotoxic risk of occupational exposure to antineoplastic drugs, chromosomal aberration (CAs) frequencies in peripheral lymphocytes were determined for 20 nurses handling antineoplastics and 18 referents matched for age and sex. Urinary cyclophosphamide (CP) excretion rates, which are used as a marker for drug handling, were also measured on these nurses. We have observed significant frequencies of CAs (about 2.5-fold increase) including chromatid breaks, gaps, and acentric fragments for nurses handling antineoplastics as compared to control subjects (p<0.05, p<0.01, excluding and including gaps, respectively). The mean value of CP excretion rate for 12 nurses was 1.63 μg/24 h, suggesting that when the nurses handled CP (and other antineoplastic drugs) this particular compound was absorbed. Our study has shown that increased genetic damage was evident in nurses, at population level, due to occupational exposure to antineoplastics. Until the effects of handling antineoplastics from low-level exposure are known, it will be important to keep the exposure to a minimum.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Kopjar, Nevenka, Davor Želježić, Vilena Kašuba und Ružica Rozgaj. „Antineoplastic Drugs as a Potential Risk Factor in Occupational Settings: Mechanisms of Action at the Cell Level, Genotoxic Effects, and Their Detection Using Different Biomarkers“. Archives of Industrial Hygiene and Toxicology 61, Nr. 1 (01.03.2010): 121–46. http://dx.doi.org/10.2478/10004-1254-61-2010-2025.

Der volle Inhalt der Quelle
Annotation:
Antineoplastični Lijekovi Kao Čimbenik Rizika u Radnom Okolišu: Mehanizmi Djelovanja na Razini Stanice i Pregled Metoda za Otkrivanje Njihovih Genotoksičnih UčinakaU članku je prikazana osnovna podjela antineoplastičnih lijekova prema mehanizmima djelovanja na razini stanice. Objašnjeni su mehanizmi genotoksičnosti najvažnijih vrsta lijekova koji se primjenjuju u okviru uobičajenih protokola za liječenje zloćudnih novotvorina. Navedena je važeća klasifikacija antineoplastika prema kancerogenom potencijalu, podaci o mutagenom potencijalu te je prikazana njihova podjela u skladu s anatomsko-terapijsko-kemijskim sustavom klasifikacije. Sustavno su prikazani najvažniji rezultati svjetskih i hrvatskih istraživanja na populacijama radnika izloženih antineoplasticima, provedenih u razdoblju 1980.-2009. s pomoću četiri najčešće primjenjivane metode: analize izmjena sestrinskih kromatida, analize kromosomskih aberacija, mikronukleus-testa i komet-testa. Objašnjena su osnovna načela navedenih metoda te raspravljene njihove prednosti i nedostaci. Biološki pokazatelji daju važne podatke o individualnoj osjetljivosti profesionalno izloženih ispitanika koji mogu poslužiti unaprjeđenju postojećih uvjeta rada i upravljanju rizicima pri izloženosti genotoksičnim agensima. Na osnovi prednosti i nedostataka citogenetičkih metoda zaključeno je da je mikronukleus-test, koji podjednako uspješno dokazuje klastogene i aneugene učinke, jedna od najboljih metoda dostupnih za otkrivanje štetnih djelovanja antineoplastičnih lijekova koji su u aktivnoj primjeni.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Guan, Xiaodong, Haishaerjiang Wushouer, Mingchun Yang, Sheng Han, Luwen Shi, Dennis Ross-Degnan und Anita Katharina Wagner. „Influence of government price regulation and deregulation on the price of antineoplastic medications in China: a controlled interrupted time series study“. BMJ Open 9, Nr. 11 (November 2019): e031658. http://dx.doi.org/10.1136/bmjopen-2019-031658.

Der volle Inhalt der Quelle
Annotation:
BackgroundIn October 2012, the Chinese government established maximum retail prices for specific products, including 30 antineoplastic medications. Three years later, in June 2015, the government abolished price regulation for most medications, including all antineoplastic medications. This study examined the impacts of regulation and subsequent deregulation of prices of antineoplastic medications in China.MethodsUsing hospital procurement data and an interrupted time series with comparison series design, we examined the impacts of the policy changes on relative purchase prices (Laspeyres price index) and volumes of and spending on 52 antineoplastic medications in 699 hospitals. We identified three policy periods: prior to the initial price regulation (October 2011 to September 2012); during price regulation (October 2012 to June 2015); and after price deregulation (July 2015 to June 2016).ResultsDuring government price regulation, compared with price-unregulated cancer medications (n=22, mostly newer targeted products), the relative price of price-regulated medications (n=30, mostly chemotherapeutic products) decreased significantly (β=−0.081, p<0.001). After the government price deregulation, no significant price change occurred. Neither government price regulation nor deregulation had a significant impact on average volumes of or average spending on all antineoplastic medications immediately after the policy changes or in the longer term (p>0.05).ConclusionCompared with unregulated antineoplastics, the prices of regulated antineoplastic medications decreased after setting price caps and did not increase after deregulation. To control the rapid growth of oncology medication expenditures, more effective measures than price regulation through price caps for traditional chemotherapy are needed.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Hong, Samuel J., Edward C. Li, Linda M. Matusiak und Glen T. Schumock. „Spending on Antineoplastic Agents in the United States, 2011 to 2016“. Journal of Oncology Practice 14, Nr. 11 (November 2018): e683-e691. http://dx.doi.org/10.1200/jop.18.00069.

Der volle Inhalt der Quelle
Annotation:
Purpose: Recent cancer drug approvals are lauded as being more effective with relatively fewer adverse effects, but these treatments come with a great cost to the US health care system. There is little information on recent trends in actual antineoplastic expenditures representative of the whole US health care system or by sector. Therefore, the objective of this study was to describe antineoplastic expenditures in the United States by year and sector. Methods: This was a retrospective, cross-sectional study of IQVIA (formerly QuintilesIMS) National Sales Perspective data for the period of January 1, 2011, to December 31, 2016. Actual expenditures were totaled by health care sector and calendar year, then adjusted for medical-cost inflation to 2016 dollars. Growth was calculated as the percentage increase from the previous year. Results: Total expenditures of antineoplastic agents across all channels grew from $26.8 billion in 2011 to $42.1 billion in 2016. Antineoplastic spending increased 12.2% in 2016 (compared with the previous year), followed by 15.6% in 2015, 13.4% in 2014, 6.3% in 2013, and 0.4% in 2012. Throughout the study period, 96.5% of total antineoplastic expenditures occurred within clinics, mail-order pharmacies, nonfederal hospitals, and retail pharmacies. Conclusion: Antineoplastic expenditures are expected to increase because of continuing development and approval of costly targeted cancer therapies. Cost containment and utilization management strategies must be balanced so as not to restrict access or disrupt innovation. Future policies should focus on ensuring safe and appropriate use of antineoplastics while balancing long-term drug costs.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Olin, Jacqueline L., Olga Klibanov, Alexandre Chan und Linda M. Spooner. „Managing Pharmacotherapy in People Living With HIV and Concomitant Malignancy“. Annals of Pharmacotherapy 53, Nr. 8 (15.02.2019): 812–32. http://dx.doi.org/10.1177/1060028019833038.

Der volle Inhalt der Quelle
Annotation:
Objective: To describe data with selected malignancies in people living with HIV (PLWH) and HIV in individuals affected by both conditions and to summarize drug-drug interactions (DDIs) with clinical recommendations for point-of-care review of combination therapies. Data Sources: Literature searches were performed (2005 to December 2018) in MEDLINE and EMBASE to identify studies of malignancies in PLWH in the modern era. Study Selection and Data Extraction: Article bibliographies and drug interaction databases were reviewed. Search terms included HIV, antiretroviral therapy, antineoplastic agents, malignancies, and drug interactions. Data Synthesis: In the pre–antiretroviral therapy (ART) era, malignancies in PLWH were AIDS-defining illnesses, and life expectancy was shorter. Nowadays, PLWH are living longer and developing malignancies, including lung, anal, and prostate cancers. Concurrently, the oncology landscape has evolved, with novel oral targeted agents and immunotherapies becoming routine elements of care. The increased need for and complexity with antineoplastics in PLWH has led to recommendations for multidisciplinary care of this unique population. Evaluation of DDIs requires review of metabolic pathways, absorption mechanisms, and various drug transporters associated with antineoplastics and ART. Relevance to Patient Care and Clinical Practice: This review summarizes available data of non–AIDS-defining malignancies, principles of HIV care in the patient with malignancy, and guidance for assessing DDIs between antineoplastics and ART. Summary DDI tables provide point-of-care recommendations. Conclusions: The availability of ART has transformed AIDS into a chronic medical condition, and PLWH are experiencing age-related malignancies. Pharmacists play an important role in the management of this patient population.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

S R, Vendra. „A Review on Venetoclax – An Antineoplastic Agent“. Journal of Medical Science And clinical Research 05, Nr. 04 (08.04.2017): 20012–15. http://dx.doi.org/10.18535/jmscr/v5i4.45.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Mehr Quellen

Dissertationen zum Thema "Antineoplastika"

1

Wan, Jung Wing. „Novel ether lipids as antineoplastic agents“. Thesis, University of Southampton, 1997. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.242627.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Danica, Jović. „Sinteza, karakterizacija i biološka ispitivanja fulerenol/doksorubicin nanokompozita“. Phd thesis, Univerzitet u Novom Sadu, Prirodno-matematički fakultet u Novom Sadu, 2018. https://www.cris.uns.ac.rs/record.jsf?recordId=106903&source=NDLTD&language=en.

Der volle Inhalt der Quelle
Annotation:
U radu je predstavljena sinteza i karakterizacija  novog fulerenol/doksorubicin nanokompozita, sintetisanog sa ciljem dobijanja potencijalne nove nanoformulacije postojećeg antineoplastika doksorubicina, koja bi pokazala veću biološku aktivnost uz smanjenje neželjenih sporednih efekata koje sam lek izaziva, na prvom mestu kardiotoksičnosti.Nanokompozit fulerenol/doksorbicin je okarakterisan brojnim  metodama prateći dva osnovna eksperimentalna pristupa: molekulsko-spektroskopske metode (XPS, denzitometrija i transportne osobine, NMR, UPLC, Ramanska i UV-spektroskopija, SFM) i metode  nanokarakterizacije (DLS, AFM, TEM), kao i računske simulacije(RDF). Osnovni cilj ispitivanja je bila detekcija postojanja nekovalentnog nanokompozita koji ostvaruju doksorubicin i fulerenolske nanočestice u vodenom rastvoru. Rezultati karakterizacije jasno i nedvosmisleno ukazuju na postojanje nekovalentnih interakcija unutar nanokompozita, što dalje utiče na organizaciju i udruživanje čestica, a što uslovljava i drugačiju biološku aktivnost takvog sistema u odnosu na pojedinačne komponente.  Rezultati bioloških ispitivanja na in vitro modelu različitih tumorskih ćelijskih linija pokazuju  značajan antiproliferativni efekat nanokompozita, kao i selektivnost prema tumorskim u odnosu na zdravu ćelijsku liniju. Eksperimenti na in vivo modelu zebrica potvrđuju smanjenje toksičnosti nanokompozita u poređenju sa lekom, primarno kardiotoksičnosti. Računske simulacije, mikroskopski i spektroskopski podaci, kao i rezultati  in vitro i in vivo studija ukazuju na to da nekovalentne interakcije između fulerenola i doksorubicina mogu biti ključni korak u stvaranju sinergističkog sistema za dostavu leka u biološki sistem.Multipotentnost fulerenola kao nanonosača lekova i nespecifičnost strukture doksorubicina kao leka, ukazuje na to da bi fulerenol mogao biti efikasan nanonosač i drugih antineoplastika, što daje prostora za unapređenje antitumorskih osobina lekova posredstvom istovremene administracije leka.
The focus of this thesis was the synthesis and characterization of a novel fullerenol/doxorubicin nanocomposite, with the aim to obtain a potential nanoformulation of antineoplastic drug doxorubicin, which would  express greater biological activity and lower level of adverse effects than the drug itself, in the first place cardiotoxicity.Nanocomposite fullerenol/doxorubicin was characterized by means of numerous methods  following two main experimental approaches: molecular-spectroscopic methods (XPS, densitometry and transport properties, NMR, UPLC, Raman and UVspectroscopy, SFM) and mehods of  anocharacterisation  (DLS, AFM,  TEM), as well as computer simulations (RDF). The goal of characterization was detection of  non-covalent interactions within nanocomposite that are established between fullerenol nanoparticles and doxorubicin in aqueous solution. The results clearly indicate the existence of non- covalent interactions within nanocomposite that affect the organization and assembling of the particles, which further exhibit different biological activity of such a system in comparison to components themselves. Results of biological activity on in vitro model of different tumor cell lines show significant antiproliferative effect of  nanocomposite, as well as selectivity towards tumor cell lines. Experiments conducted on in vivo zebrafish model confirm the lowering ofthe adverse effects of the drug, especially cardiotoxicity, in case when nanocomposite was applied. Computer simulations, microscopic and  spectroscopic results combined with encouraging in vitro and in vivo results point out  that non-covalent interactions between fullerenol nanoparticles and doxorubicin may present the keyrole in formation of a synergistic system for nanodrug delivery into biological system. Multipotential of fullerenol nanoparticles as a nanocarrier and non-specific structure of doxorubicin as a drug imply that fullerenol may serve as a efficient nanocarrier of numerous other antineoplastics, which further allows the improvement of antitumor properties of drugs withsimultaneous drug administration.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Conesa, Milián Laura. „Synthesis of combretastatin analogues with antineoplastic properties“. Doctoral thesis, Universitat Jaume I, 2019. http://hdl.handle.net/10803/667097.

Der volle Inhalt der Quelle
Annotation:
This doctoral thesis belongs to the field of medicinal and pharmacological chemistry. Its aim is the synthesis, characterization and biological evaluation of three families of aminocombretastatin derivatives, compound with antimitotic and antiangiogenic properties. The first group contains a carbamate function in its structure. These derivatives have been studied as antimitotic and vascular disrupting agents. The second family has been designed from sorafenib drug, with the aim of studying its antiangiogenic effects. Regarding the third family, these have been designed as multitarget compounds, with both antiangiogenic and immunomodulatory properties. Finally, in vivo studies have been developed with the aim of knowing all the perspectives of a biological evaluation process. In conclusion, several compounds have been obtained from the same general structure, able to interact with different targets involved in cancer disease, thus improving the effect offered by aminocombretastatin.
Esta tesis doctoral se enmarca en el campo de la química médica y farmacológica. Tiene como objetivo la síntesis, caracterización y evaluación biológica de tres familias de derivados de aminocombretastatina, compuesto con propiedades antimitóticas y antiangiogénicas. El primer grupo contiene una función carbamato en su estructura. Estos se han estudiado como agentes antimitóticos y disruptores de la vasculatura. La segunda familia se ha diseñado a partir del fármaco sorafenib, con el objetivo de estudiar sus efectos antiangiogénicos. Respecto a la tercera familia, se trata de compuestos multidiana, con propiedades antiangiogénicas e inmunomoduladoras. Finalmente, se han desarrollado estudios in vivo con el objetivo de conocer todas las perspectivas de un proceso de evaluación biológica. Como conclusión, destacar que a partir de una misma estructura general se han obtenido varios compuestos que interactúan con diferentes dianas involucradas en la enfermedad del cáncer, mejorando así pues el efecto ofrecido por la aminocombretastatina.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Molyneux, Gemma. „Studies on the haemotoxicity of antineoplastic agents“. Thesis, University College London (University of London), 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.435080.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Hedmer, Maria. „Monitoring of occupational exposure to antineoplastic drugs“. Malmö : Lund University, 2006. http://theses.lub.lu.se/scripta-archive/2006/04/18/med_1298/Maria_H_kappa.pdf.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Chen, Alina. „New polyamine analogues as potential antineoplastic agents“. Scholarly Commons, 2000. https://scholarlycommons.pacific.edu/uop_etds/2680.

Der volle Inhalt der Quelle
Annotation:
The naturally occurring polyamines play an essential role in cell growth and proliferation. The levels of polyamines have been shown to increase in rapidly proliferating cancer cells. Therefore, compounds that inhibit enzymes in polyamine biosynthetic pathway may have therapeutic potential. Compounds capable of providing both in vitro and in vivo inhibition of almost all enzymes in the polyamine biosynthetic pathway are known. An exception is the lack of an agent that inhibits spermidine/spermine N 1 -acetyltransferase (SSAT), the rate-limiting enzyme in the catabolism of polyamines. The design, synthesis and characterization of five new polyamine analogues as potential inhibitors of SSAT are presented. Three compounds, N 1 -[3-(propenamido) propyl]-1,4-diaminobutane dihydrochloride 5 , N 1 -[3-(maleimido)propyl]-1,4-diamino-butane dihydrochloride 7 and N 1 -[3-(2-bromoacetamido)propyl]-1,4-diaminobutane dihydrochloride 9 , were designed as active-site-directed affinity label inhibitors. Two compounds, N-[N-(5-acetamido-2-hydroxypentyl-3-aminopropyl)]-1,4-diaminobutane trihydrochloride 12 and N-[3-(2-hydroxyethylamino)propyl]-1,4-diaminobutane trihydrochloride 14 , were designed as transition state-like analogue inhibitors. These compounds were synthesized using one key intermediate, N-(3-aminopropyl)-N,N ′ -bis-(tert-butoxycarbonyl)-1,4-diaminobutane 3 . Three of these synthesized compounds, 5 , 7 and 12 were evaluated for their ability to inhibit SSAT. The enzyme used was a crude extract of human large cell undifferentiated lung carcinoma cell line NCI H157 cells. These synthetic analogues when tested against the crude enzyme extract at concentrations of 0.05, 0.1, 1 and 5 μM appeared to show no effects on the activity of SSAT.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Bossaer, John B. „Addressing Potential Interactions Between Antineoplastics and Dietary Supplements“. Digital Commons @ East Tennessee State University, 2015. https://doi.org/10.2146/ajhp140295.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Rey, Allan W. „Synthetic studies directed towards the antineoplastic macrolide bryostatins“. Thesis, University of Ottawa (Canada), 1990. http://hdl.handle.net/10393/5938.

Der volle Inhalt der Quelle
Annotation:
This thesis describes stereocontrolled and practical routes to the C(1)-C(9), C(17)-C(20), and C(21)-C(27) synthons of bryostatins, which are a closely related family of 20-membered ring lactones embedding 1,3-polyol units. Bryostatins are isolated in minute quantities from the marine Bryozoan Bugula neritina and possess exceptional antineoplastic activity. Membrane-enclosed enantioselective enzymatic hydrolysis was successfully employed for the generation of gram quantities of the versatile building block (3R)-methoxymethoxypentadioic acid, monomethyl ester (51) (Chapter 2). This compound was used in the synthesis of the C(1)-C(5) segment of bryostatins. Preliminary synthetic studies towards the C(1)-C(9) subunit are described in Chapter 3. Wittig and dithiane approaches were unfortunately unsuccessful for the connection of an enzymatically derived 5 carbon unit with a D-pantolactone derived 4 carbon unit. Chapter 4 describes the practical synthesis of the C(1)-C(9) fragment of bryostatin in forms suitable for both structure/activity studies and synthetic elaboration. The pivotal step utilized a diastereoselective Mukaiyama aldol condensation of a diketene derived silylenol ether with an enzymatically derived chiral $\beta$-alkoxyaldehyde. Chapter 5 details the conversion of D-pantolactone and of D-galactono-1,4-lactone into the C(17)-C(20) and C(21)-C(27) synthons of bryostatins via a chiron approach. A study of nucleophilic additions onto chiral substituted $\gamma$-lactol templates is discussed in Chapter 6. This provided valuable information regarding the coupling of the C(17)-C(20) and C(21)-C(27) segments of bryostatins. As well, the results demonstrate the potential utility of $\gamma$-lactols as templates--a relatively unexplored area in asymmetric synthetic chemistry.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Parker-, Johnson Kitani A. „An evaluation of novel antineoplastic agent on prostate cancer“. DigitalCommons@Robert W. Woodruff Library, Atlanta University Center, 2003. http://digitalcommons.auctr.edu/dissertations/3074.

Der volle Inhalt der Quelle
Annotation:
This study examines the effects of novel antineoplastic agents(isochalcones) on human metastatic prostate cancer cell lines by screening cells for their relative antiproliferative effects, measuring the protein expression levels of specific oncogenes by Western blotting, and evaluating an array of genes ( 5184) to determine possible mechanisms of action of these novel isochalcones. The array data were supported by real-time polymerase chain reaction (PCR) techniques. The antineoplastic agents were screened in human metastatic prostate cancer cell lines (LNCaP, DU145, PC-3, and MDA-PCa-2b) and non-cancerous prostate epithelial cell line PZ-HPV-7 in concentrations ranging from nanomolar to millimolar. The alamar blue exclusion dye assay, a redox indicator, was used to evaluate cell proliferation when compared to the untreated control. DJ52 demonstrated a growth inhibitory effect on LNCaP, PC-3, and DU145 cell lines at the micromolar concentration (p<0.05). Based on these data, 1 x 106 cells were treated, protein isolated, and expression levels of epidermal growth factor (EGF) and omithine decarboxylase (ODC) were measured and compared to theuntreated controls. These data indicated a dose-dependent decrease of expression of EGF and ODC, therefore, suggesting that other key oncogenes may also have a decrease in expression when treated with these novel antineoplastic agents. Therefore, gene arrays were used to identify possible families of genes and/or specific pathways that may be responsible for the antiproliferative effects noted. It was determined that the key families of genes significantly induced by these agents (Pathways 4®) were proapoptotic and cell cycle regulators. ABI 7700 Prism was used to perform quantitative RT-PCR via the AB Sequence Detector® software.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Arshad, Usman [Verfasser]. „Population pharmacokinetic modeling to understand antineoplastic treatment / Usman Arshad“. Bonn : Universitäts- und Landesbibliothek Bonn, 2020. http://d-nb.info/1239730233/34.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Mehr Quellen

Bücher zum Thema "Antineoplastika"

1

Lednicer, Daniel. Antineoplastic Drugs. Chichester, UK: John Wiley & Sons, Ltd, 2015. http://dx.doi.org/10.1002/9781118892572.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Antineoplastic drugs: Organic syntheses. Chichester, West Sussex: Wiley, 2015.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Chow, Nang-Ly. Liposomes as carriers of antineoplastic agents and immunomodulators. Bethesda, MD: U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, International Cancer Research Data Bank, 1989.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Some antiviral and antineoplastic drugs, and other pharmaceutical agents. Lyon, France: IARC, 2000.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Horgan, Carmel Mary Teresa. Studies on Mitozolomide (CCRG 81010), a new antineoplastic agent. Birmingham: University of Aston.Department of Pharmacy, 1985.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Markman, Maurie. Regional antineoplastic drug delivery in the management of malignant disease. Baltimore: Johns Hopkins University Press, 1991.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Thurston, David E. Chemistry and pharmacology of anticancer drugs. Boca Raton: Taylor & Francis, 2007.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Fund, Pacific West Cancer, und National Cancer Coalition, Hrsg. Camptotheca acuminata: China's 'tree of joy' offers hope in the U.S. Seattle, Wash: Distributed by National Cancer Coalition, 1997.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Kang ai xin yao yan jiu zhi nan: New drugs in development for cancers. Beijing: Ke xue chu ban she, 2009.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Arab, Sara. Studies of the antineoplastic activity of verotoxin in vitro and in vivo. Ottawa: National Library of Canada = Bibliothèque nationale du Canada, 1997.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Mehr Quellen

Buchteile zum Thema "Antineoplastika"

1

Markman, Maurie. „Das Dosis-Wirkung-Prinzip in Verbindung mit der Zufuhr von Antineoplastika“. In Regionale Therapie maligner Tumoren, 21–26. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/978-3-642-35014-6_2.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Patsalos, Philip N. „Antineoplastic Agents“. In Antiepileptic Drug Interactions, 253–62. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-32909-3_61.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Patsalos, P. N. „Antineoplastic Agents“. In Antiepileptic Drug Interactions, 319–32. London: Springer London, 2012. http://dx.doi.org/10.1007/978-1-4471-2434-4_57.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

O'brien, Wendy Pott. „Antineoplastic Agents“. In Physiologically Based Pharmacokinetic Modeling, 297–317. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2005. http://dx.doi.org/10.1002/0471478768.ch11.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Schmähl, D., M. R. Berger, B. K. Keppler und T. Klenner. „New Antineoplastic Agents“. In Cancer Therapy, 95–110. Berlin, Heidelberg: Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-642-74683-3_11.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Patel, Jai N., Christine M. Walko und Federico Innocenti. „Pharmacogenetics and Antineoplastic Therapies“. In Advances in Predictive, Preventive and Personalised Medicine, 275–305. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-15344-5_10.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Dhakal, Sughosh, Daniel Weiner, Cindy Schwartz und Louis S. Constine. „Pulmonary Effects of Antineoplastic Therapy“. In Pediatric Oncology, 201–27. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-16435-9_11.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Gerić, Marko, Goran Gajski und Verica Garaj Vrhovac. „Toxicity of Antineoplastic Drug Mixtures“. In Fate and Effects of Anticancer Drugs in the Environment, 421–39. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-21048-9_17.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Haddad, Tufia, und Douglas Yee. „Basic Principles of Antineoplastic Therapies“. In Breast Surgical Techniques and Interdisciplinary Management, 707–15. New York, NY: Springer New York, 2010. http://dx.doi.org/10.1007/978-1-4419-6076-4_58.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Gescher, Andreas, Lincoln L. H. Tsang und John A. Slack. „The Metabolism of Antineoplastic Triazenes“. In Triazenes, 91–96. Boston, MA: Springer US, 1990. http://dx.doi.org/10.1007/978-1-4615-3832-5_7.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen

Konferenzberichte zum Thema "Antineoplastika"

1

Ditto, Andrew J., Nikki K. Robbishaw, Matthew J. Panzner, Wiley J. Youngs und Yang H. Yun. „Targeting Ovarian Cancer Cells With Rapidly Biodegradable L-Tyrosine Polyphosphate Nanoparticles Decorated With Folate“. In ASME 2011 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2011. http://dx.doi.org/10.1115/sbc2011-53138.

Der volle Inhalt der Quelle
Annotation:
Chemotherapy employs toxic chemicals to kill rapidly dividing cells. Examples of FDA approved antineoplastic drugs include cisplatin, doxorubicin, and paclitaxel. Since most of these drugs are nonspecific, they also damage normal tissues as well as the aberrant tumors. As a result, non-specific therapies have multiple side effects, which include myelosuppression, mucositis, alopecia, nephrotoxicity, and genotoxcity. In order to minimize these issues, researchers have begun to conjugate antineoplastic chemicals with targeting moieties or encapsulate drugs into nanoparticles decorated with compounds, peptides, or proteins that recognize specific cellular receptors, which are upregulated by the neoplastic cells. The targeting moieties aid in the accumulation of these drugs within the blood vessels of carcinomas, while keeping concentrations low in the systemic circulation. Thus, targeted delivery systems are able to minimize the unwanted side effects and increase the efficacy of chemotherapies.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Sieber, Fritz. „Antineoplastic And Antiviral Properties Of Merocyanine 540“. In O-E/Fiber LASE '88, herausgegeben von Tayyaba Hasan. SPIE, 1989. http://dx.doi.org/10.1117/12.960195.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Medina, Luis Alberto. „Liposomes as delivery systems for antineoplastic drugs“. In XIII MEXICAN SYMPOSIUM ON MEDICAL PHYSICS. AIP Publishing LLC, 2014. http://dx.doi.org/10.1063/1.4901357.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Alonso Castro, V., B. López Centeno, I. Martín Casasempere, D. Alioto, A. Gil Martín, M. Segura Bedmar, A. Aranguren Oyarzábal und MJ Calvo Alcántara. „4CPS-105 Prescribed antineoplastic agents in paediatric patients“. In 24th EAHP Congress, 27th–29th March 2019, Barcelona, Spain. British Medical Journal Publishing Group, 2019. http://dx.doi.org/10.1136/ejhpharm-2019-eahpconf.254.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Deroubaix, F., T. Ameye, V. Moinard und J. Gressier. „PP-048 Antineoplastics: anticipated preparations or longer opening hours?“ In 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.495.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Labrèche, F., B. Roberge, A. Yennek, NJ Caron und J.-F. Bussières. „1508 Is hospital sanitation personnel exposed to antineoplastic agents?“ In 32nd Triennial Congress of the International Commission on Occupational Health (ICOH), Dublin, Ireland, 29th April to 4th May 2018. BMJ Publishing Group Ltd, 2018. http://dx.doi.org/10.1136/oemed-2018-icohabstracts.923.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Yoon, Seug Yun, Namsu Lee, Sook-Ja Kim, Hee-Jeong Cheong, Kyoung Ha Kim und Jong-Ho Won. „Abstract 3843: Pulmonary toxicities of molecular targeted antineoplastic agents“. In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-3843.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Pires, T., D. Almeida, J. Joaquim, J. Lopes und C. Matos. „PP-052 Surface contamination of antineoplastics due to working procedures“. In 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.499.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Ochiuz, Lacramioara. „FORMULATION AND CHARACTERIZATION OF NEW MODIFIED-RELEASE TOPICAL ANTINEOPLASTIC PRODUCTS“. In 18th International Multidisciplinary Scientific GeoConference SGEM2018. Stef92 Technology, 2018. http://dx.doi.org/10.5593/sgem2018/6.1/s24.029.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Bradley, Cathy J., und Marcelo Coca Perraillon. „Abstract PR10: Fewer rural cancer patients treated with antineoplastic agents“. In Abstracts: Eleventh AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; November 2-5, 2018; New Orleans, LA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7755.disp18-pr10.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen

Berichte der Organisationen zum Thema "Antineoplastika"

1

Huang, Yi. Antineoplastic Efficacy of Novel Polyamine Analogues in Human Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, Juni 2004. http://dx.doi.org/10.21236/ada427952.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Huang, Yi. Antineoplastic Efficacy of Novel Polyamine Analogues in Human Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, Juni 2006. http://dx.doi.org/10.21236/ada460069.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Huang, Yi. Antineoplastic Efficacy of Novel Polyamine Analogues in Human Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, Juni 2007. http://dx.doi.org/10.21236/ada478464.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Berger, Martin R. Antineoplastic activity of cucurbitacin I in CC531 rat colorectal cancer cells. Science Repository OÜ, März 2019. http://dx.doi.org/10.31487/j.cor.2019.01.105.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Koutcher, Jason A. Non-Invasive Markers of Tumor Growth, Metastases and Sensitivity to AntiNeoplastic Therapy. Fort Belvoir, VA: Defense Technical Information Center, Januar 2006. http://dx.doi.org/10.21236/ada460278.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Antineoplastic agents - occupational hazards in hospitals. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, September 2004. http://dx.doi.org/10.26616/nioshpub2004102.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, September 2004. http://dx.doi.org/10.26616/nioshpub2004165.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, September 2004. http://dx.doi.org/10.26616/nioshpub2004165a.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

NIOSH list of antineoplastic and other hazardous drugs in healthcare settings, 2016. (Supersedes 2014-138). U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, September 2016. http://dx.doi.org/10.26616/nioshpub2016161.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2010 (superseded by 2012-150). U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, September 2010. http://dx.doi.org/10.26616/nioshpub2010167.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Die Auswahlen zum Thema "Antineoplastika" für konkrete Quellenarten können Sie auch interessieren:
Zeitschriftenartikel Dissertationen Bücher
Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!

Zur Bibliographie